Welcome to study of the week, a new series from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is…
Recently, scientists have been exploring a more genetically-based underlying cause of pancreatic cancer. Now, according to Medical XPress, researchers are deepening their understanding of genetics and pancreatic cancer in relation…
The latest news from Israeli scientists, published in the Times of Israel, is that researchers at Tel Aviv University have accurately targeted cancerous cells in mice using CRISPR.…
A study conducted by researchers from the Institute of Cancer Research in London and Cyclacel has recently been published in PLOS ONE. This investigation examined fadraciclib as a potential therapy…
One huge goal throughout the medical world is to find effective and well-tolerated treatments for patients with cancer. According to News Medical, researchers recently discovered one beneficial treatment for…
An NIH news release shared that a study on polycystic ovarian syndrome (polycystic ovary syndrome or PCOS) discovered that the condition might have two distinct subtypes based on genetic mutations. Through…
In her early 20's, Mackenzie Alleman lost her mother to breast cancer. Then, at 28, she herself underwent a preventative double mastectomy after learning that she carried the mutated BRCA1 gene.…
Merck and AstraZeneca recently announced that Lynparza improved overall survival in the lives of males with advanced prostate cancer who had been treated previously. The drug out-performed two other antiandrogen…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
